These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18544424)

  • 1. Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors.
    Kenet G; Martinowitz U
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S38-41. PubMed ID: 18544424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose recombinant factor VIIa therapy in hemophilia patients with inhibitors.
    Kenet G
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S108-10. PubMed ID: 16427376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, observational, post-approval registry of inhibitor patients treated with multiple or single doses of recombinant activated factor VII.
    Chambost H
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S35-7. PubMed ID: 18544423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
    Abshire TC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):3-7. PubMed ID: 14872413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors.
    Shapiro AD
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):579-86. PubMed ID: 18820600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
    Young G; Cooper DL; Gut RZ;
    Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
    Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
    Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa (NovoSeven) as a hemostatic agent.
    Hedner U
    Dis Mon; 2003 Jan; 49(1):39-48. PubMed ID: 12525827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
    Łaguna P; Mital A
    Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.
    Hedner U; Brun NC
    Neuroradiology; 2007 Oct; 49(10):789-93. PubMed ID: 17653706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
    Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
    J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.
    Faranoush M; Abolghasemi H; Mahboudi F; Toogeh G; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi BK; Mehrvar A; Khoeiny B; Vaziri B; Kamyar K; Heshmat R; Baghaeipour MR; Mirbehbahani NB; Fayazfar R; Ahmadinejad M; Naderi M
    Clin Appl Thromb Hemost; 2016 Mar; 22(2):184-90. PubMed ID: 25343955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
    Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
    Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
    Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience.
    Rodriguez-Merchan EC; Jimenez-Yuste V; Gomez-Cardero P; Alvarez-Roman M; Martin-Salces M; Rodriguez de la Rua A
    Haemophilia; 2010 May; 16(102):84-8. PubMed ID: 20536990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
    Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.